Shinozuka K

Psychedelics Restructure the Global Workspace of Consciousness

Yousefi P, Shinozuka K, Vizeli P +8

Ultrasonic potentiation of ketamine neuromodulation

Roy KS, Martinez P, Ewbank SN +4

Dynamic Substates of the Default Mode Network Are Associated with Mystical Experiences and Clinical Outcomes after Magnesium-Ibogaine Treatment in Veterans with Traumatic Brain Injury

Shinozuka K, Olash C, Han T +16

ArticleMescaline

Psychedelic Therapy: A Primer for Primary Care Clinicians-Mescaline.

Tabaac BJ, Shinozuka K, Fadel M +3

Indication-stratified mortality risk of ibogaine treatment under contemporary safety protocols: a multisite analysis of 19,071 patients and updated systematic review of fatalities

Arns M, Shinozuka K, Barsuglia J

Ibogaine is associated with reorganization of high-beta brain networks in veterans with post-traumatic stress disorder

Shinozuka K, Rosso M, Chaiken A +14

ArticleDMT

Psychedelic Therapy: A Primer for Primary Care Clinicians-5-Methoxy-N,N-Dimethyltryptamine.

Tabaac BJ, Shinozuka K, Weisman A +3

PreprintMescaline

Psychedelic Therapy: A Primer for Primary Care Clinicians—Mescaline

Tabaac BJ, Shinozuka K, Fadel +3

PreprintPsychedelics

Psychedelics are associated with changes in spiritual beliefs and orientations in US veterans

Brown RE, Shinozuka K, Kaloiani I +4

ArticlePsychedelics

Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.

Shinozuka K, Jerotic K, Mediano P +4

PreprintDMT

Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT)

Tabaac BJ, Shinozuka K, Weisman A +3

ArticleKetamine

Mapping the Use of Ketamine in Treatment-Resistant Depression and Other Psychiatric Disorders: A Scoping Review of Practice Patterns, Efficacy, and Patient Demographic Trends.

Aslam AM, Shinozuka K, Muir O +1

ArticleLSD

The Role of the Dorsolateral Prefrontal Cortex in Ego Dissolution and Emotional Arousal During the Psychedelic State.

Coleman CR, Shinozuka K, Tromm R +7

LSD reconfigures the frequency-specific network landscape of the human brain

Shinozuka K, Rosso M, Coleman CR +8

ArticleLSD

LSD flattens the hierarchy of directed information flow in fast whole-brain dynamics.

Shinozuka K, Tewarie PKB, Luppi A +7

Mapping the Use of Ketamine in Treatment-Resistant Depression and Other Psychiatric Disorders: A Scoping Review of Practice Patterns, Efficacy, and Patient Demographic Trends

Aslam A, Shinozuka K, Muir OS +1

The Role of the Dorsolateral Prefrontal Cortex in Ego Dissolution and Emotional Arousal During the Psychedelic State

Coleman CR, Shinozuka K, Tromm R +7

ArticlePsilocybin

Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.

Shinozuka K, Jerotic K, Mediano P +4

LSD flattens the hierarchy of directed information flow in fast whole-brain dynamics

Shinozuka K, Tewarie PK, Luppi A +7

ArticlePsilocybin

Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.

Tabaac BJ, Shinozuka K, Arenas A +5

ArticleAyahuasca

Psychedelic Therapy: A Primer for Primary Care Clinicians-N,N-Dimethyltryptamine and Ayahuasca.

Shinozuka K, Tabaac BJ, Arenas A +5

ArticleLSD

Psychedelic Therapy: A Primer for Primary Care Clinicians-Lysergic Acid Diethylamide (LSD).

Beutler BD, Shinozuka K, Tabaac BJ +5

ArticlePsilocybin

Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.

Tabaac BJ, Shinozuka K, Arenas A +5

ArticleKetamine

Psychedelic Therapy: A Primer for Primary Care Clinicians-Ketamine.

Evans VD, Arenas A, Shinozuka K +5

ArticleIbogaine

Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine.

Cherian K, Shinozuka K, Tabaac BJ +5

ArticleKetamine

Psychedelic Therapy: A Primer for Primary Care Clinicians-The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics.

Muir OS, Shinozuka K, Beutler BD +5

ArticleMDMA

Psychedelic Therapy: A Primer for Primary Care Clinicians-3,4-Methylenedioxy-methamphetamine (MDMA).

Shinozuka K, Tabaac BJ, Arenas A +5

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part VII. Ketamine

Evans VD, Arenas A, Shinozuka K +5

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part VIII. The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics

Muir OS, Shinozuka K, Beutler BD +5

PreprintAyahuasca

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part III. N,N-dimethyltryptamine (DMT) and Ayahuasca

Shinozuka K, Tabaac BJ, Arenas A +5

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part I. Historical Perspective and Overview

Tabaac BJ, Shinozuka K, Arenas A +5

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part V. Ibogaine

Cherian K, Shinozuka K, Tabaac BJ +5

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part II. Lysergic acid diethylamide (LSD)

Beutler BD, Shinozuka K, Tabaac BJ +5

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part IV. Psilocybin

Tabaac BJ, Shinozuka K, Arenas A +5

PreprintMDMA

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part VI. 3,4-methylenedioxy-methamphetamine (MDMA)

Shinozuka K, Tabaac BJ, Arenas A +5

Synergistic, Multi-level Understanding of Psychedelics: Three Systematic Reviews and Meta-analyses of Their Pharmacology, Neuroimaging and Phenomenology

Shinozuka K, Jerotic K, Mediano P +4